Atkins repositioned to target lapsed GLP-1 users as sales slide

· Agriculture & Food · United States

Simply Good Foods is repositioning its Atkins weight-loss brand to reach consumers who have stopped using GLP-1 obesity drugs. The shift comes as the parent company struggles to capitalize on recent health trends, with Atkins sales dropping 20.9% in its 2026 fiscal year. GLP-1 drugs have reshaped appetite and diet behavior, pressuring legacy weight-management brands whose low-carb positioning competes with pharmaceutical appetite suppression. Atkins is now aiming at the population that used such drugs and left them, a segment the company sees as underserved. The repositioning signals how food brands are reworking strategies around the fast-growing GLP-1 market.

Why it matters：GLP-1 drugs are reshaping demand in weight-management food, and how legacy brands reposition will test whether they can retain shelf relevance.

Key points

  • Atkins sales fell 20.9% in the 2026 fiscal year.
  • The brand now targets people who have stopped using GLP-1 drugs.

Sources (original reporting)

More stories from this day